for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion



The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or metastatic solid tumors. The study will consist of 2 parts: ABBV-368 dose escalation and ABBV-368 tumor-specific dose expansion (triple negative breast cancer [TNBC] cohort and head and neck cancer cohort).

Official Title

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors


Recruitment is closed in Part 1A; subjects are in maintenance.


Advanced Solid Tumors Cancer Solid Tumors Cancer Metastatic Solid Tumors Advanced Solid Tumors Triple negative breast cancer (TNBC) Ovarian cancer Hepatocellular carcinoma (HCC) Gastric cancer Mesothelioma Small cell lung cancer (SCLC) Cholangiocarcinoma Merkel cell carcinoma Melanoma Non-small cell lung cancer (NSCLC) Neoplasms ABBV-368 ABBV-181


You can join if…

Open to people ages 18 years and up

  • Participants must have histologic or cytology diagnosis of a known immunogenic solid tumor, as described for Part 1 Dose Escalation and Part 2 Cohort Expansion:
  • Part 1 Dose Escalation:
  • Participants with advanced or metastatic solid tumors that have exhausted standard treatment for their incurable disease and for whom there is currently no programmed cell death 1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) approved therapy, with immunogenic type tumors such as, but not limited to triple negative breast cancer(TNBC), ovarian cancer, small cell lung cancer, mesothelioma, and cholangiocarcinoma.
  • Participants who are refractory to a PD-1/PD-L1 agent, with tumor types such as melanoma, NSCLC, platinum-pretreated head and neck cancer, second line bladder and RCC.
  • Part 2A and 2B Cohort Expansion:
  • 2A : TNBC ABBV-368 monotherapy cohorts: Subjects with locally advanced or metastatic TNBC that have exhausted standard treatment for their incurable disease.
  • 2B : Head and Neck cohort: Participants with recurrent squamous cell head and neck carcinoma that are not candidates for curative treatment with local or systemic therapy, or metastatic (disseminated) head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2.
  • Participants must have immune-related Response Evaluation Criteria for Solid Tumors(iRECIST) evaluable or measurable disease in the PART 1 and measurable disease per iRECIST in PART 2
  • Adequate bone marrow, kidney and liver function.

You CAN'T join if...

  • Received anticancer therapy including chemotherapy, immunotherapy, radiation therapy,biologic, herbal therapy, or any investigational therapy within a period of 21 days prior to the first dose of ABBV-368.
  • Prior treatment with an OX40 targeting agent.
  • has known uncontrolled metastases to the central nervous system (CNS).
  • History of active autoimmune disorders and other conditions that compromise or impair the immune system.
  • Confirmed positive test results for human immunodeficiency virus (HIV), or subjects with chronic or active hepatitis B or C. Subjects who have a history of hepatitis B or C who have documented cures after anti-viral therapy may be enrolled.
  • Has received live vaccine within 28 days prior to the first dose of study drug.


  • Ucsd /Id# 201334 not yet accepting patients
    La Jolla California 92037 United States
  • Stanford University /ID# 206949 not yet accepting patients
    Stanford California 94305 United States


accepting new patients
Start Date
Completion Date
Phase 1
Study Type
Last Updated